CCL28 and gastric cancer: The study of Ji et al. [56] demonstrated an immunoregulatory role of β-catenin signaling in GC and suggested the therapeutic potential of CCL28 blockade for the treatment of GC, because this chemokine was proved to be as a key linker between the oncogenic β-catenin signaling and the GC microenvironment.